Literature DB >> 16109514

Nitrite-derived nitric oxide by xanthine oxidoreductase protects the liver against ischemia-reperfusion injury.

Ping Lu1, Fang Liu, Zhong Yao, Chun-You Wang, Dao-Da Chen, Yuan Tian, Jing-Hui Zhang, Yi-Hua Wu.   

Abstract

BACKGROUND: It was demonstrated that xanthine oxidoreductase (XOR), during ischemia, catalyzes the formation of nitric oxide (NO) from nitrite (NO2-) and this NO2- -derived NO protects the isolated perfused rat heart against the damaging effects of ischemia-reperfusion (I/R) when conventional nitric oxide synthase (NOS)-dependent NO production is impaired. Liver is one of the organs with the highest XOR concentration. This study was designed to determine whether NO2- -derived NO by XOR protects liver against I/R injury in vivo. For its minute amounts and active reactivity, NO can not be detected directly in real time in vivo by this time. We have to prove the above hypothesis indirectly.
METHODS: Wistar rats were pretreated with saline, NOS inhibitor L-NAME (10 mg/kg intravenously), XOR inhibitor allopurinol (1.5 mg/kg orally), L-NAME +allopurinol and NO scavenger carboxy-PTIO (0.6 mg/kg intravenously) respectively (12 animals per group). And then, they were subjected to total liver ischemia for 40 minutes followed by reperfusion. Blood samples and liver tissues were obtained for analysis after 3 hours of reperfusion. Survival was also investigated.
RESULTS: Allopurinol-treated animals exhibited further increased serum alanine aminotransferase(ALT) levels and liver myeloperoxidase(MPO) activities, but further decreased liver adenosine triphosphate(ATP) stores after I/R compared to saline-treated counterparts (830.5+/-108.3 U/L, 56.5+/-11.0 U/mg protein and 1.93+/-0.47 mumol/g vs. 505.8+/-184.2 U/L, 41.5+/-10.2 U/mg protein and 3.05+/-0.55 micromol/g respectively, P < 0.01, P < 0.05 and P < 0.01 respectively). The hepatocyte injury was further exacerbated and the overall survival rate was significantly decreased after I/R in animals given by allopurinol compared to those pretreated by saline (P < 0.05). L-NAME and allopurinol co-treated animals exhibited more severe liver injury (P < 0.05 and P<0.01)and a further decreased overall survival rate (P < 0.05)compared to L-NAME or allopurinol alone-treated counterparts, but they were not different from carboxy-PTIO treated animals (P > 0.05).
CONCLUSION: NO2- -derived NO by XOR in the hypoxic and acidic environment induced by hepatic I/R protects the liver against I/R injury in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109514

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  33 in total

Review 1.  Nitrates and nitrites in the treatment of ischemic cardiac disease.

Authors:  Vaughn E Nossaman; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Jul-Aug       Impact factor: 2.644

Review 2.  Nitrite as a mediator of ischemic preconditioning and cytoprotection.

Authors:  Daniel Murillo; Christelle Kamga; Li Mo; Sruti Shiva
Journal:  Nitric Oxide       Date:  2011-01-26       Impact factor: 4.427

Review 3.  Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective.

Authors:  Kejing Chen; Roland N Pittman; Aleksander S Popel
Journal:  Antioxid Redox Signal       Date:  2008-07       Impact factor: 8.401

4.  Dietary supplementation with sodium nitrite can exert neuroprotective effects on global cerebral ischemia/reperfusion in mice.

Authors:  Takasuke Fukuda; Manabu Kakinohana; Chitoshi Takayama; Masayuki Matsushita; Kazuhiro Sugahara
Journal:  J Anesth       Date:  2015-01-08       Impact factor: 2.078

5.  How to protect liver graft with nitric oxide.

Authors:  Hassen Ben Abdennebi; Mohamed Amine Zaoualí; Izabel Alfany-Fernandez; Donia Tabka; Joan Roselló-Catafau
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

Review 6.  Potential of dietary nitrate in angiogenesis.

Authors:  Christos Rammos; Peter Luedike; Ulrike Hendgen-Cotta; Tienush Rassaf
Journal:  World J Cardiol       Date:  2015-10-26

7.  Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2.

Authors:  Courtney E Sparacino-Watkins; Jesús Tejero; Bin Sun; Marc C Gauthier; John Thomas; Venkata Ragireddy; Bonnie A Merchant; Jun Wang; Ivan Azarov; Partha Basu; Mark T Gladwin
Journal:  J Biol Chem       Date:  2014-02-05       Impact factor: 5.157

Review 8.  Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how.

Authors:  Nadiezhda Cantu-Medellin; Eric E Kelley
Journal:  Nitric Oxide       Date:  2013-02-27       Impact factor: 4.427

Review 9.  Clinical translation of nitrite therapy for cardiovascular diseases.

Authors:  John W Calvert; David J Lefer
Journal:  Nitric Oxide       Date:  2009-11-10       Impact factor: 4.427

10.  Vascular effects of dietary nitrate (as found in green leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway.

Authors:  Satnam Lidder; Andrew J Webb
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.